17 clinical trials
grid
list
download
- Title Organ Phase Statut Major inclusion criteria Contact
- 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1
- 1407 GUCC TIGER A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors Testicles phase 3 Closed Germ cell tumor
- AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1
- ANITA A phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosphorine-based first line chemotherapy for inoperable disease Multiple phase 2 Closed second line metastatic
- BIA-ALCL Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry Lymphoma Open Breast implants
- Brightline-1 A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma (Brightline-1 ; 1403-0008) sarcome phase 2/3 Open
- EORTC 1658 Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Lung Closed any line / Lung metastasis
- EZH-202 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Soft tissue phase 2 Closed after standard therapy
- IJB_2728 Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention Solid tumors Open Metastatic, any tumors
- Intervention destinée aux parents L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité Solid tumors Open Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors
-
LuMEn
The LuMEn study 177Lu-octreotate treatment outcome prediction using Multimodality imaging in refractory neuroEndocrine tumours
Multiple
phase
3
Closed
*Radiological progression RECIST 1.1 over the last 12 months
*Disease progression on a PET/CT or SPECT/CT over the last 12 months
*at least one lesion with hight tumour uptake on Ga-octreotate PET/CT and morphologically measurable according to RECIST1.1 - NBTXR3-301 Nanobiotix A multicentre randomized, open-label Phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall sarcome phase 2/3 Closed Subject is able to receive radiotherapy and surgery
- NIR-DT-301 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors (DTs)/Aggressive Fibromatosis (AF) Soft tissue phase 3 Closed RECIST v1.1
- OX2016-203-01 An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors Multiple phase 1 Closed Any line/RECIST v1.1/Eligible for platinium salt chemotherapy